Challenges  ||| S:0 E:11 ||| NNS
comparing  ||| S:11 E:21 ||| VBG
functional  ||| S:21 E:32 ||| JJ
limitations  ||| S:32 E:44 ||| NNS
in  ||| S:44 E:47 ||| IN
rheumatoid  ||| S:47 E:58 ||| JJ
arthritis  ||| S:58 E:68 ||| NN
and  ||| S:68 E:72 ||| CC
ankylosing  ||| S:72 E:83 ||| JJ
spondylitis  ||| S:83 E:95 ||| NN
Whether  ||| S:95 E:103 ||| IN
physical  ||| S:103 E:112 ||| JJ
functioning  ||| S:112 E:124 ||| NN
in  ||| S:124 E:127 ||| IN
patients  ||| S:127 E:136 ||| NNS
with  ||| S:136 E:141 ||| IN
rheumatoid  ||| S:141 E:152 ||| JJ
arthritis  ||| S:152 E:162 ||| NN
( ||| S:162 E:163 ||| -LRB-
RA ||| S:163 E:165 ||| NNP
)  ||| S:165 E:167 ||| -RRB-
differs  ||| S:167 E:175 ||| VBZ
from  ||| S:175 E:180 ||| IN
that  ||| S:180 E:185 ||| DT
in  ||| S:185 E:188 ||| IN
patients  ||| S:188 E:197 ||| NNS
with  ||| S:197 E:202 ||| IN
ankylosing  ||| S:202 E:213 ||| JJ
spondylitis  ||| S:213 E:225 ||| NNS
( ||| S:225 E:226 ||| -LRB-
AS ||| S:226 E:228 ||| NNP
)  ||| S:228 E:230 ||| -RRB-
is  ||| S:230 E:233 ||| VBZ
presently  ||| S:233 E:243 ||| RB
uncertain ||| S:243 E:252 ||| JJ
.  ||| S:252 E:254 ||| .
Such  ||| S:254 E:259 ||| PDT
a  ||| S:259 E:261 ||| DT
comparison  ||| S:261 E:272 ||| NN
poses  ||| S:272 E:278 ||| VBZ
challenges ||| S:278 E:288 ||| NNS
,  ||| S:288 E:290 ||| ,
not  ||| S:290 E:294 ||| RB
only  ||| S:294 E:299 ||| RB
because  ||| S:299 E:307 ||| IN
the  ||| S:307 E:311 ||| DT
two  ||| S:311 E:315 ||| CD
diseases  ||| S:315 E:324 ||| NNS
differ  ||| S:324 E:331 ||| VBP
in  ||| S:331 E:334 ||| IN
the  ||| S:334 E:338 ||| DT
domains  ||| S:338 E:346 ||| NN
of  ||| S:346 E:349 ||| IN
functioning  ||| S:349 E:361 ||| VBG
affected ||| S:361 E:369 ||| VBN
,  ||| S:369 E:371 ||| ,
but  ||| S:371 E:375 ||| CC
also  ||| S:375 E:380 ||| RB
because  ||| S:380 E:388 ||| IN
of  ||| S:388 E:391 ||| IN
the  ||| S:391 E:395 ||| DT
different  ||| S:395 E:405 ||| JJ
instruments  ||| S:405 E:417 ||| NNS
used  ||| S:417 E:422 ||| VBN
to  ||| S:422 E:425 ||| TO
measure  ||| S:425 E:433 ||| VB
functional  ||| S:433 E:444 ||| JJ
limitations ||| S:444 E:455 ||| NNS
.  ||| S:455 E:457 ||| .
Limiting  ||| S:457 E:466 ||| VBG
our  ||| S:466 E:470 ||| PRP$
analysis  ||| S:470 E:479 ||| NN
to  ||| S:479 E:482 ||| TO
studies  ||| S:482 E:490 ||| NNS
using  ||| S:490 E:496 ||| VBG
similar  ||| S:496 E:504 ||| JJ
self-report  ||| S:504 E:516 ||| JJ
questionnaires ||| S:516 E:530 ||| NN
,  ||| S:530 E:532 ||| ,
we  ||| S:532 E:535 ||| PRP
examined  ||| S:535 E:544 ||| VBD
published  ||| S:544 E:554 ||| VBN
observational  ||| S:554 E:568 ||| JJ
studies  ||| S:568 E:576 ||| NNS
of  ||| S:576 E:579 ||| IN
unselected  ||| S:579 E:590 ||| JJ
cohorts  ||| S:590 E:598 ||| NNS
of  ||| S:598 E:601 ||| IN
patients  ||| S:601 E:610 ||| NNS
with  ||| S:610 E:615 ||| IN
RA  ||| S:615 E:618 ||| NNP
and  ||| S:618 E:622 ||| CC
patients  ||| S:622 E:631 ||| NNS
with  ||| S:631 E:636 ||| IN
AS  ||| S:636 E:639 ||| NNP
to  ||| S:639 E:642 ||| TO
compare  ||| S:642 E:650 ||| VB
and  ||| S:650 E:654 ||| CC
contrast  ||| S:654 E:663 ||| NN
the  ||| S:663 E:667 ||| DT
severity  ||| S:667 E:676 ||| NN
of  ||| S:676 E:679 ||| IN
functional  ||| S:679 E:690 ||| JJ
limitations ||| S:690 E:701 ||| NNS
.  ||| S:701 E:703 ||| .
Available  ||| S:703 E:713 ||| JJ
studies  ||| S:713 E:721 ||| NNS
from  ||| S:721 E:726 ||| IN
a  ||| S:726 E:728 ||| DT
few  ||| S:728 E:732 ||| JJ
direct  ||| S:732 E:739 ||| JJ
comparisons ||| S:739 E:750 ||| NNS
,  ||| S:750 E:752 ||| ,
and  ||| S:752 E:756 ||| CC
mostly  ||| S:756 E:763 ||| RB
indirect  ||| S:763 E:772 ||| JJ
comparisons ||| S:772 E:783 ||| NNS
,  ||| S:783 E:785 ||| ,
suggested  ||| S:785 E:795 ||| VBD
that  ||| S:795 E:800 ||| IN
patients  ||| S:800 E:809 ||| NNS
with  ||| S:809 E:814 ||| IN
RA  ||| S:814 E:817 ||| NNP
are  ||| S:817 E:821 ||| VBP
generally  ||| S:821 E:831 ||| RB
more  ||| S:831 E:836 ||| RBR
severely  ||| S:836 E:845 ||| RB
limited  ||| S:845 E:853 ||| VBN
in  ||| S:853 E:856 ||| IN
physical  ||| S:856 E:865 ||| JJ
functioning  ||| S:865 E:877 ||| NN
throughout  ||| S:877 E:888 ||| IN
the  ||| S:888 E:892 ||| DT
disease  ||| S:892 E:900 ||| NN
course  ||| S:900 E:907 ||| NN
than  ||| S:907 E:912 ||| IN
patients  ||| S:912 E:921 ||| NNS
with  ||| S:921 E:926 ||| IN
AS ||| S:926 E:928 ||| NNP
.  ||| S:928 E:930 ||| .
Since  ||| S:930 E:936 ||| IN
most  ||| S:936 E:941 ||| JJS
studies  ||| S:941 E:949 ||| NNS
did  ||| S:949 E:953 ||| VBD
not  ||| S:953 E:957 ||| RB
adjust  ||| S:957 E:964 ||| VB
adequately  ||| S:964 E:975 ||| RB
for  ||| S:975 E:979 ||| IN
potentially  ||| S:979 E:991 ||| RB
important  ||| S:991 E:1001 ||| JJ
confounders ||| S:1001 E:1012 ||| NN
,  ||| S:1012 E:1014 ||| ,
such  ||| S:1014 E:1019 ||| JJ
as  ||| S:1019 E:1022 ||| IN
age ||| S:1022 E:1025 ||| NN
,  ||| S:1025 E:1027 ||| ,
gender ||| S:1027 E:1033 ||| NN
,  ||| S:1033 E:1035 ||| ,
comorbidity ||| S:1035 E:1046 ||| NN
,  ||| S:1046 E:1048 ||| ,
and  ||| S:1048 E:1052 ||| CC
disease  ||| S:1052 E:1060 ||| NN
duration ||| S:1060 E:1068 ||| NN
,  ||| S:1068 E:1070 ||| ,
reported  ||| S:1070 E:1079 ||| VBD
differences  ||| S:1079 E:1091 ||| NNS
in  ||| S:1091 E:1094 ||| IN
functional  ||| S:1094 E:1105 ||| JJ
disability  ||| S:1105 E:1116 ||| NN
between  ||| S:1116 E:1124 ||| IN
patients  ||| S:1124 E:1133 ||| NNS
with  ||| S:1133 E:1138 ||| IN
RA  ||| S:1138 E:1141 ||| NNP
and  ||| S:1141 E:1145 ||| CC
patients  ||| S:1145 E:1154 ||| NNS
with  ||| S:1154 E:1159 ||| IN
AS  ||| S:1159 E:1162 ||| NNP
must  ||| S:1162 E:1167 ||| MD
be  ||| S:1167 E:1170 ||| VB
interpreted  ||| S:1170 E:1182 ||| VBN
cautiously ||| S:1182 E:1192 ||| RB
.  ||| S:1192 E:1194 ||| .
